ORYZON Hosting Key Opinion Leader Webinar on Targeting Lysine Specific Demethylase 1 (LSD1) in CNS and Psychiatric Disorders and Oncology
Retrieved on:
Wednesday, February 22, 2023
Newton, Clinical trial, Beth Israel Deaconess Medical Center, LSD1, Central nervous system, Principal, MD, University, Genomics, Medical school, Associate, PI, DSM-IV codes, Eastern Time Zone, Acute myeloid leukemia, CNS, ISIN, Gene expression, ORY, AML, Medical director, Mass, Hospital Clinic Manuel Quintela, Vall, Johns Hopkins University, Psychiatry, Borderline personality disorder, Societat Catalana de Gnomònica, Universitat (Barcelona Metro), Pharmaceutical industry, Nursing, Greater Boston, Medicine, Hematology, Schizophrenia, Neurology
The event will focus on Oryzon’s Phase 2 programs: vafidemstat, an LSD1 inhibitor optimized for CNS and psychiatric disorders, and iadademstat, a selective LSD1 inhibitor for oncology.
Key Points:
- The event will focus on Oryzon’s Phase 2 programs: vafidemstat, an LSD1 inhibitor optimized for CNS and psychiatric disorders, and iadademstat, a selective LSD1 inhibitor for oncology.
- He completed his Residency and Clinic for Psychiatry, followed by his Clinic for Neurology, at the University-Hospital Frankfurt am Main.
- She has worked as a hematologist at Vall d’ Hebron University Hospital in Barcelona, Spain since 2010, mainly focused on acute myeloid leukemias.
- She has been participating in more than 15 clinical trials as PI, with special interest in early-phase clinical trials.